Inhibitor of melanocyte-stimulating hormone (MSH) release. Blocks the release of α
-MSH, increases brain dopamine levels and antagonizes physiological and behavioral opioid effects in vivo
(Modifications: Gly-3 = C-terminal amide)
Desiccate at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Inhibitory influences of FMRFamide and PLG on stress-induced opioid analgesia and activity.
Kavaliers and Hirst
Brain Res., 1986;372:370
Pharmacology of L-Prolyl-L-Leucyl-Glycinamide (PLG): a review.
Mishra et al.
Methods Find.Exp.Clin.Pharmacol., 1983;5:203
Synthetic melanocyte stimulating hormone release inhibiting factor (MIF). Part III: effect of L-prolyl-N-methyl-D-leucyl-glycinamide and MIF on biogenic amine turnover.
Pugsley and Lippmann
Pharmacological studies with a tripeptide, Prolyl-Leucyl Glycine amide.
Plotnikoff and Kastin